The purpose of this guideline is to provide a practical framework that can be applied for the identification, categorisation, qualification and control of mutagenic impurities to limit potential carcinogenic risk.
This guideline is intended to complement ICH Q3A(R2), 9 Q3B(R2) (note 1), and ICH M3(R2): non-clinical safety studies for the conduct of human clinical trials and marketing authorisations for pharmaceuticals.
|Download document||International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guideline M7 on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk – Step 3|
|Status||draft: consultation open|
|Consultation start date||22/02/2013|
|Consultation end date||20/06/2013|
|Email address for firstname.lastname@example.org|